Kidoguchi Satoshi
Division of Nephrology and Hypertension, Department of Internal Medicine, The Jikei University School of Medicine, Tokyo, Japan.
Hypertens Res. 2025 Jun;48(6):1988-1990. doi: 10.1038/s41440-025-02197-w. Epub 2025 Mar 26.
Lenvatinib, a multi-tyrosine kinase inhibitor approved for the treatment of multiple cancer types, can induce hypertension, which can be a prognostic indicator in patients with hepatocellular carcinoma. Further research into the mechanism of anticancer drug-induced blood pressure elevation is necessary and patients should be managed by a multi-disciplinary "Onco-Hypertension" team.
乐伐替尼是一种被批准用于治疗多种癌症类型的多靶点酪氨酸激酶抑制剂，它可引发高血压，而高血压可能是肝细胞癌患者的一项预后指标。有必要进一步研究抗癌药物所致血压升高的机制，并且应由一个多学科的“肿瘤高血压”团队对患者进行管理。
